- « Previous
- Clinical Pharmacology
- Next »
Zithromax
CLINICAL PHARMACOLOGY
Zithromax
Pharmacokinetics
Following oral administration of a single 500 mg dose (two 250 mg tablets) to 36 fasted healthy male volunteers, the mean (SD) pharmacokinetic parameters were AUC0-72 = 4.3 (1.2) µg·h/mL; Cmax = 0.5 (0.2) µg/mL; Tmax = 2.2 (0.9) hours.
With a regimen of 500 mg (two 250 mg capsules*) on day 1, followed by 250 mg daily (one 250 mg capsule) on days 2 through 5, the pharmacokinetic parameters of azithromycin in plasma in healthy young adults (18-40 years of age) are portrayed in the chart below. Cmin and Cmax remained essentially unchanged from day 2 through day 5 of therapy.
| Pharmacokinetic Parameters (Mean) | Total n=12 | |
| Day 1 | Day 5 | |
| Cmax (µg/mL) | 0.41 | 0.24 |
| Tmax (h) | 2.5 | 3.2 |
| AUC0-24 (µg•h/mL) | 2.6 | 2.1 |
| Cmin (µg/mL) | 0.05 | 0.05 |
| Urinary Excret. (% dose) | 4.5 | 6.5 |
| *Azithromycin 250 mg tablets are bioequivalent to 250 mg capsules in the fasted state. Azithromycin 250 mg capsules are no longer commercially available. | ||
In a two-way crossover study, 12 adult healthy volunteers (6 males, 6 females) received 1,500 mg of azithromycin administered in single daily doses over either 5 days (two 250 mg tablets on day 1, followed by one 250 mg tablet on days 2-5) or 3 days (500 mg per day for days 1-3). Due to limited serum samples on day 2 (3-day regimen) and days 2-4 (5-day regimen), the serum concentration-time profile of each subject was fit to a 3-compartment model and the AUC0-∞ for the fitted concentration profile was comparable between the 5-day and 3-day regimens.
| Pharmacokinetic Parameter [mean (SD)] | 3-Day Regimen | 5-Day Regimen | ||
| Day 1 | Day 3 | Day 1 | Day 5 | |
| Cmax (serum, µg/mL) | 0.44 (0.22) | 0.54 (0.25) | 0.43 (0.20) | 0.24 (0.06) |
| Serum AUC0-∞ (µg•hr/mL) | 17.4 (6.2)* | 14.9 (3.1)* | ||
| Serum T1/2 | 71.8 hr | 68.9 hr | ||
| *Total AUC for the entire 3-day and 5-day regimens | ||||
Median azithromycin exposure (AUC0-288) in mononuclear (MN) and polymorphonuclear (PMN) leukocytes following either the 5-day or 3-day regimen was more than a 1000-fold and 800-fold greater than in serum, respectively. Administration of the same total dose with either the 5-day or 3-day regimen may be expected to provide comparable concentrations of azithromycin within MN and PMN leukocytes.
Two azithromycin 250 mg tablets are bioequivalent to a single 500 mg tablet.
Absorption
The absolute bioavailability of azithromycin 250 mg capsules is 38%.
In a two-way crossover study in which 12 healthy subjects received a single 500 mg dose of azithromycin (two 250 mg tablets) with or without a high fat meal, food was shown to increase Cmax by 23% but had no effect on AUC.
When azithromycin suspension was administered with food to 28 adult healthy male subjects, Cmax increased by 56% and AUC was unchanged.
Generic Name: Azithromycin
- « Previous
- Clinical Pharmacology
- Next »
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Boost Your Immune System
Your immune system attacks foreign invaders with specialized white blood cells. Find out how to use diet and exercise to help. See more WebMD Videos »
